Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements
01/04/2026 22:18
April 1 (Reuters) - Alto Neuroscience Inc ANRO.N: ALTO NEUROSCIENCE REPORTS TOPLINE DATA FROM PHASE 2 PROOF-OF-CONCEPT STUDY OF ALTO-101 AND HIGHLIGHTS PIPELINE ADVANCEMENTS ALTO NEUROSCIENCE INC: IN PROOF-OF-CONCEPT STUDY, ALTO-101 DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT ALTO NEUROSCIENCE INC: DEVELOPMENT OF ALTO-207 REMAINS TOP PRIORITY FOR COMPANY; PHASE 2B ON TRACK TO INITIATE IN 1H 2026 ALTO NEUROSCIENCE:DEVELOPED MODIFIED-RELEASE, ONCE-DAILY ORAL FORMULATION OF ALTO-101,PLANS TO EXPLORE PARTNERING OPPORTUNITIES FOR THIS FORMULATION Source text: ID:nBw8hp3h9a Further company coverage: ANRO.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements